Daniel Bertholet
Senior Investment Director @ Endeavour Vision
Geneva, Switzerland
Daniel Bertholet is an Investment Director in the Life Sciences practice at Endeavour Vision, with a focus on medtech investments. Daniel has invested in PneumRx, Symetis, CeQur, Nfocus (sold to Covidien), Endoart (sold to Allergan), Thommen Medical (exited), Neocutis (sold to Merz Pharma), Novalar Pharmaceuticals (exited) and Kuros Biosurgery. Healso participated in investments and/or follow-on investments in Native Networks (sold to Alcatel), eProject/Daptiv (exited), Paion (IPO), Nexx Systems (sold to Tokyo Electron) and Novimmune.Prior to his venture capital career, Daniel was the co-founder and CFO of a technology start-up and has invested as a business angel/private investor in private companies for over 15 years in Europe and the US. Daniel started his career as a consultant in country risk assessment for Business Environment Risk Intelligence (BERI) in the US and Switzerland.Daniel is a member of the Medtech Task Force of the European Venture Capital Association (EVCA) and has been on the Selection Committee of the Medtech Summits of the European Techtour in 2008, 2010, 2012, 2013 and on the Steering Committee of the OneMedForum conferences in the USA. Daniel has been asked to speak at industry events in US and Europe.Daniel holds an MBA with honours from the Institut d’Etudes Politiques in Paris and a MA in International Political Economy from the American University in Washington DC.Daniel is personally committed to support vulnerable children in Sub-Saharan Africa. He lives in Geneva with his wife and their three children.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Daniel Bertholet invests in
Stages Daniel Bertholet invests in
Countries Daniel Bertholet invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 4 (100%)
- Biotechnology 3 (75%)
- Medical 2 (50%)
- Medical Device 2 (50%)
- Beauty 1 (25%)
Stage
- Series A 1 (25%)
- Series C 1 (25%)
- Funding Round 1 (25%)
- Post-IPO Equity 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| ReShape Lifesciences is America's premier weight-loss solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® System provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical staplingprocedures such as the gastric bypass or sleeve gastrectomy. The ReShape Vest™ System is an investigational (outside the U.S.) minimally invasive, laparoscopically implanted medical device that wraps around the stomach, emulating the gastric volume reduction effect of conventional weight-loss surgery. It helps enable rapid weight loss in obese and morbidly obese patients without permanently changing patient anatomy. T | $38M / Post-IPO Equity / Aug 26, 2015 | ||
| PneumRx, Inc., a start-up medical device company, develops minimally invasive treatments for emphysema patients. The company develops RePneu Lung Volume Reduction Coil, an investigational device for treating emphysema patients. PneumRx, Inc. was founded in 2004 and is based in Mountain View, California. | $33M / Jan 04, 2011 | ||
Nfocus Neuromedical
|
Nfocus Neuromedical, Inc. designs, develops, and markets endovascular neurosurgery solutions to cure intracranial aneurysms. The company offers revolutionary systems to treat neurovascular disease, including brain aneurysms. The company was formerly known as CardioVasc, Inc. and changed its name to Nfocus Neuromedical, Inc. in April 2007. Thecompany was incorporated in 1997 and is based in Palo Alto, California. As of February 19, 2013, Nfocus Neuromedical, Inc. operates as a subsidiary of Covidien plc. | Series C / Sep 13, 2010 | |
| NEOCUTIS is dedicated to being the most admired, trusted and innovative physician-dispensed skincare brand. NEOCUTIS strives to fulfill this mission by developing exclusive technology platforms based on cutting-edge scientific research. Incorporating targeted technologies into luxurious product formulas enables NEOCUTIS to deliver innovativeskincare solutions that address key skincare concerns, including the signs of aging, discoloration, oxidative stress, skin redness and dryness. | Series A / Jun 15, 2004 |
Co-Investors
About Endeavour Vision
Endeavour Vision is a private equity firm investing in growth-stage MedTech and digital health companies. The company invests in medical innovation that provides superior clinical benefits for patients or brings significant efficiencies to health systems. Endeavour Vision team offers strategic and operational expertise and extensive internationalexperience investing in companies in Europe and North America. We have a proven track record of successful exits with recently realized investments that include Vertiflex (acquired by Boston Scientific in 2019), Medartis (IPO on SIX in Q1 2018), and Symetis (acquired by Boston Scientific in 2017). Endeavour Vision’s offices are located in Geneva, Switzerland, and Minneapolis, U.S.
Endeavour Vision Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alex Schmitz
Partner
|
|||
Bernard Vogel
Founder and Managing Partner
|
|||
Damien Tappy
President & Managing Partner
|
|||
Daniel van den Bergh
Senior Investment Director
|
|||
Fernando Pacheco
Investment Director
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Daniel Bertholet invest in?
Daniel Bertholet invests primarily in Health Care, Biotechnology and Medical startups, most often at Series A and Series C stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Daniel Bertholet?
Public channels for Daniel Bertholet include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Daniel Bertholet last invest?
The most recent investment recorded for Daniel Bertholet closed in Aug 2015. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
